Thermedical’s Pulsed Field Ablation Study Now Complete

Thermedical has completed a feasibility study utilizing Pulsed Field Ablation (PFA) therapy in combination with its SERF Ablation System and Durablate Catheter to treat ventricular tachycardia (VT), an abnormally rapid heart rhythm that is a leading cause of sudden cardiac death worldwide.
 
PFA is an emerging technique that harnesses pulsed electrical field energy to deliver swift and precise tissue ablation in the heart’s thin layers.
 
“We are encouraged by the results from our pre-clinical feasibility study evaluating PFA technology integrated into our SERF Ablation System with the Durablate Catheter. We believe this combination therapy will show promise in improving the management of people with VT, potentially offering new hope for people who live with this challenging condition,” Thermedical Co-Founder/CEO Michael Curley, Ph.D., said. “The incorporation of PFA into Thermedical’s Durablate Catheter, featuring advanced electrode configurations, reinforces our commitment to advancing cardiac ablation technologies. Our Durablate Catheter’s design enables targeted ablation of previously untreated tissue layers. PFA in combination with our clinically tested SERF Ablation method may improve therapeutic outcomes.”
 
Thermedical’s SERF ablation with the Durablate catheter is being evaluated as a treatment option for patients with ventricular arrhythmias resistant to antiarrhythmic drugs or standard ablation procedures.¹ SERF ablation provides a new, more efficient form of biological heat transfer than conventional ablation methods. The Durablate catheter delivers energy with a high level of accuracy to treat tissue deeper in the heart wall where life-threatening arrhythmias that cause VT are often located.
 
The addition of PFA therapy to SERF ablation may offer a more complete approach to VT ablation and a practice-changing technology.

“With this preliminary feasibility study, the SERF system with the Durablate in combination with PFA therapy showed the potential to be an efficient option for treating VT,” said Dr. William H. Sauer, section chief, Cardiac Arrhythmia Service of Brigham and Women’s Hospital. “We are excited about the study’s result and the potential of PFA therapy to supplement the promise that SERF Ablation has previously shown.”
 
Thermedical is a privately held company founded by Curley, a Massachusetts Institute of Technology (MIT) Hyperthermia Center alumnus, and Patrick S. Hamilton, Ph.D. Under a Massachusetts Life Sciences Center Small Business Matching Grant (SBMG) Award, multiple NIH Small Business Innovation Research (SBIR) Grants, and Series A venture funding, the Waltham, Mass.-based company has developed thermal-ablation systems to treat ventricular tachycardia and solid tumors. 

Reference 
¹ https://clinicaltrials.gov/study/NCT05337241?term=Thermedical&rank=2